Correlation between serum hypersensitive C-reactive protein, lipoprotein-related phospholipase A2 and senile essential hypertension complicated with type 2 diabetes

doi:10.3969/j.issn.1004-583X.2021.01.005

Abstract

Abstract:

Objective To investigate the correlation between serum hypersensitive C-reactive protein(HS-CRP), lipoprotein-associated phospholipase A₂(LP-PLA₂) and senile essential hypertension(EH) complicated with type 2 diabetes mellitus (T2DM). Methods A total of 128 EH patients aged ≥60 years were selected as research subjects. According to whether T2DM was combined, the patients were divided into simple EH group (n=60) and EH+DM group (n=68). Patients with pure T2DM during the same period were selected as pure DM group (n=63) and healthy physical examinees as control group (n=61). The differences of FPG, HbA₁c, hs-CRP, Lp-PLA₂ in EH patients with T2DM in different hypertensive subgroups were analyzed. The differences of FPG, HbA₁c, systolic blood pressure(SBP), diastolic blood pressure(DBP) in hs-CRP and Lp-PLA₂ subgroups were analyzed. The correlation between hs-CRP, Lp-PLA₂ and HbA₁c, SBP and DBP was analyzed. Results In EH+DM group, EH group and DM group, LDL-C, hs-CRP and Lp-PLA₂ were all higher than those in control group, while HDL-C was lower than that in control group (all P<0.05). In EH+DM patients, FPG, HbA₁c, hs-CRP and Lp-PLA₂ were all increased with the increase of hypertension level(all P<0.05). With the increase of hs-CRP level, FPG, HbA₁c and SBP all increased (all P<0.05). With the increase of Lp-PLA₂ level, both SBP and DBP increased (all P<0.05). Hs-CRP was positively correlated with HbA₁c, SBP and DBP. Lp-PLA₂ was positively correlated with HbA₁c, SBP, and DBP.At the same time, HbA₁c was positively correlated with SBP and DBP. After adjusting for age, gender, smoking history, body mass index(BMI) and triglyceride(TG), the elevated levels of hs-CRP and Lp-PLA₂ were the risk factors for EH combined with T2DM (all P<0.05). Conclusion The levels of hs-CRP and Lp-PLA₂ can predict the severity of EH combined with T2DM to a certain extent, and hs-CRP and Lp-PLA₂ are risk factors of EH combined with T2DM, which can reflect the patients’ blood pressure, blood glucose control and hypertension classification.

Key words: hypertension, diabetes melittus, type 2, C-reactive protein, phospholipase A₂

CLC Number:

R544.1

Liu Xiaoteng, Shan Weichao, Hou Ruitian, Lin Jinping, Gao Yu, Jin Fengbiao, Liu Chang. Correlation between serum hypersensitive C-reactive protein, lipoprotein-related phospholipase A₂and senile essential hypertension complicated with type 2 diabetes[J]. Clinical Focus, 2021, 36(1): 25-29.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.01.005

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I1/25

Figures/Tables 5

References 17

[1]	He QH, Dong M, Pan Q, et al. Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 diabetes mellitus[J]. Minerva Endocrinol, 2019,44(3):252-258.
[2]	Xue X, Qiu Y, Cao SZ, et al. Detection and significance of TNF-α and hs-CRP in the pleural effusion of patients with diabetes and pulmonary tuberculosis[J]. Eur J Inflamm, 2019,17:1-5.
[3]	Qiao J, Zhou K C, Huang C, et al. Comparison of serum Lp-PLA₂ levels in ischemic stroke patients with H-type hypertension or non-H-type hypertension[J]. J Clin Lab Anal, 2020,34(2):23068.
[4]	中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志, 2011,39(7):579-616.
[5]	翁建平. 中国2型糖尿病防治指南(2013年版)[J]. 中华内分泌代谢杂志, 2014,30(10):893-942.
[6]	刘旭帮, 张朝华, 赵信科. 老年高血压合并冠心病患者同型半胱氨酸、胱抑素C与颈部血管超声指标的关系[J]. 中国老年学杂志, 2019,39(22):5397-5400.
[7]	Mehmet NA, Sedat A, Ali Ü, et al. Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes[J]. Life Sci, 2019,231:116577. doi: 10.1016/j.lfs.2019.116577 URL
[8]	AlRubeaan K, Youssef AM, Ibrahim HM, et al. All-cause mortality and its risk factors among type 1 and type 2 diabetes mellitus in a country facing diabetes epidemic[J]. Diabetes Res Clin Pract, 2016,118:130-139. doi: 10.1016/j.diabres.2016.06.012 URL
[9]	Chen Z, Zhao GH, Zhang YK, et al. Research on the correlation of diabetes mellitus complicated with osteoporosis with lipid metabolism, adipokines and inflammatory factors and its regression analysis[J]. Eur Rev Med Pharmacol Sci, 2017,21(17):3900-3905. doi: 13353 pmid: 28975973
[10]	He QH, Dong M, Pan Q, et al. Correlation between changes in inflammatory cytokines and the combination with hypertension in patients with type 2 diabetes mellitus[J]. Minerva Endocrinol, 2019,44(3):252-258.
[11]	Bakirci EM, Degirmenci H, Hamur H, et al. New inflammatory markers for prediction of non-dipper blood pressure pattern in patients with essential hypertension: Serum YKL-40/Chitinase 3-like protein 1 levels and echocardiographic epicardial adipose tissue thickness[J]. Clin Exp Hypertens, 2015,37(6):505-510. doi: 10.3109/10641963.2015.1013122 URL
[12]	Hanan E, Azza MA, Inas MT, et al. Inflammatory markers and control of type 2 diabetes mellitus.Diabetes & metabolic syndrome[J]. Diabetes Metab Syndr, 2019,13(1):800-804. doi: 10.1016/j.dsx.2018.11.061 URL
[13]	Ali S, Khan MA Khan, MA, et al. CRP, an inflammatory biomarker in type 2 diabetes mellitus[J]. JPMI, 2015,29(1):18-23.
[14]	Li ZM, Liu JG, Shen YS, et al. Increased Lipoprotein-associated phospholipase A₂ activity portends an increased risk of resistant hypertension[J]. Lipids Health Dis, 2016,15(1):1-5. doi: 10.1186/s12944-015-0172-5 URL
[15]	Tsai WC, Lin CC, Huang YY. et al. Association of lipoprotein-associated phospholipase A₂ with central aortic pressure but not peripheral blood pressure in essential hypertension[J]. Atheroscler Suppl, 2007,8(1):107.
[16]	Saswati D, Gupta SK, Girish MP, et al. A comparison of lipoprotein associated phospholipase A₂ and high sensitive C-reactive protein levels between diabetic and non-diabetic patients with coronary artery disease[J]. Endocr Abstr, 2014,35.
[17]	周学玲, 张紫晨, 邱雪婷, 等. 初诊2型糖尿病患者脂蛋白相关磷脂酶A₂与胰岛素抵抗的相关性研究[J]. 南京医科大学学报(自然科学版), 2020,40(5):681-686.

组别		例数		女[例(%)]		年龄(岁)	吸烟[例(%)]		BMI(kg/m²)		FPG(mmol/L)
对照组		61		30(49.2)		66.38±4.77	33(54.1)		24.57±3.01		5.29±0.60
DM组		63		31(49.2)		65.63±3.04	36(57.1)		24.60±2.86		8.75±1.93
EH组		60		31(51.7)		67.40±4.41	30(50.0)		26.13±3.67		5.35±0.57
EH+DM组		68		32(47.1)		65.53±4.75	37(54.4)		26.85±4.10^*#		8.56±1.34
χ²/F值				0.271		2.499	0.642		6.964		147.298
P值				0.956		0.060	0.887		<0.01		<0.01
组别	例数		HbA₁c(%)		SBP(mmHg)			DBP(mmHg)		TG(mmol/L)		LDL-C(mmol/L)
对照组	61		5.26±0.84		126.62±10.34			76.90±7.57		1.87±0.94		2.14±0.43
DM组	63		8.66±1.87		127.15±9.87			80.37±8.78		2.11±1.33		2.55±0.77^*
EH组	60		5.30±0.74		155.60±16.48			93.75±9.39		1.89±0.87		2.52±0.92^*
EH+DM组	68		9.02±1.63		162.15±17.35			93.97±12.07		2.69±2.16^*▲		2.97±0.57^*#▲
F值			141.831		112.540			53.538		4.512		15.465
P值			<0.01		<0.01			<0.01		0.004		<0.01
组别	例数		HDL-C(mmol/L)		AST(U/L)			Scr(μmol/L)		hs-CRP(mg/dl)		Lp-PLA₂(μg/L)
对照组	61		1.47±0.40		25.79±8.66			60.14±11.18		1.24±0.19		158.50±15.68
DM组	63		1.06±0.31^*		29.32±26.08			55.91±15.25		2.89±2.44^*		196.63±24.06^*
EH组	60		1.10±0.24^*		25.05±9.39			68.51±16.76		3.26±0.65^*		191.69±49.69^*
EH+DM组	68		1.02±0.27^*		29.12±14.85			68.50±19.72		4.07±1.65^*#▲		208.62±19.12^*▲
F值			28.221		1.144			9.624		38.341		32.533
P值			<0.01		0.332			<0.01		<0.01		<0.01

组别		例数		女[例(%)]		年龄(岁)	吸烟[例(%)]		BMI(kg/m²)		FPG(mmol/L)
对照组		61		30(49.2)		66.38±4.77	33(54.1)		24.57±3.01		5.29±0.60
DM组		63		31(49.2)		65.63±3.04	36(57.1)		24.60±2.86		8.75±1.93
EH组		60		31(51.7)		67.40±4.41	30(50.0)		26.13±3.67		5.35±0.57
EH+DM组		68		32(47.1)		65.53±4.75	37(54.4)		26.85±4.10^*#		8.56±1.34
χ²/F值				0.271		2.499	0.642		6.964		147.298
P值				0.956		0.060	0.887		<0.01		<0.01
组别	例数		HbA₁c(%)		SBP(mmHg)			DBP(mmHg)		TG(mmol/L)		LDL-C(mmol/L)
对照组	61		5.26±0.84		126.62±10.34			76.90±7.57		1.87±0.94		2.14±0.43
DM组	63		8.66±1.87		127.15±9.87			80.37±8.78		2.11±1.33		2.55±0.77^*
EH组	60		5.30±0.74		155.60±16.48			93.75±9.39		1.89±0.87		2.52±0.92^*
EH+DM组	68		9.02±1.63		162.15±17.35			93.97±12.07		2.69±2.16^*▲		2.97±0.57^*#▲
F值			141.831		112.540			53.538		4.512		15.465
P值			<0.01		<0.01			<0.01		0.004		<0.01
组别	例数		HDL-C(mmol/L)		AST(U/L)			Scr(μmol/L)		hs-CRP(mg/dl)		Lp-PLA₂(μg/L)
对照组	61		1.47±0.40		25.79±8.66			60.14±11.18		1.24±0.19		158.50±15.68
DM组	63		1.06±0.31^*		29.32±26.08			55.91±15.25		2.89±2.44^*		196.63±24.06^*
EH组	60		1.10±0.24^*		25.05±9.39			68.51±16.76		3.26±0.65^*		191.69±49.69^*
EH+DM组	68		1.02±0.27^*		29.12±14.85			68.50±19.72		4.07±1.65^*#▲		208.62±19.12^*▲
F值			28.221		1.144			9.624		38.341		32.533
P值			<0.01		0.332			<0.01		<0.01		<0.01

高血压分级	例数	FPG(mmol/L)	HbA₁c(%)	hs-CRP(mg/dl)	Lp-PLA₂(μg/L)
高血压1级	26	7.16±1.25	7.85±1.12	3.04±0.93	194.82±14.26
高血压2级	21	8.62±0.39^*	8.94±0.59^*	4.11±1.10^*	208.84±10.68^*
高血压3级	21	9.66±1.21^*#	10.55±1.67^*#	5.31±1.96^*#	225.47±17.89^*#
F值		22.299	29.327	15.947	25.768
P值		<0.01	<0.01	<0.01	<0.01

高血压分级	例数	FPG(mmol/L)	HbA₁c(%)	hs-CRP(mg/dl)	Lp-PLA₂(μg/L)
高血压1级	26	7.16±1.25	7.85±1.12	3.04±0.93	194.82±14.26
高血压2级	21	8.62±0.39^*	8.94±0.59^*	4.11±1.10^*	208.84±10.68^*
高血压3级	21	9.66±1.21^*#	10.55±1.67^*#	5.31±1.96^*#	225.47±17.89^*#
F值		22.299	29.327	15.947	25.768
P值		<0.01	<0.01	<0.01	<0.01

项目	例数	FPG(mmol/L)	HbA₁c(%)	SBP(mmHg)	DBP(mmHg)
hs-CRP
低分位组	84	6.08±1.83	6.13±1.98	129.05±11.29	78.17±8.00
中分位组	88	7.05±1.95^*	7.07±2.08^*	146.76±18.48^*	89.95±10.69^*
高分位组	80	8.07±2.02^*#	8.25±2.22^*#	154.63±23.96^*#	91.09±13.40^*
F值		21.634	21.018	41.265	36.221
P值		<0.01	<0.01	<0.01	<0.01
Lp-PLA₂
低分位组	84	5.88±1.48	5.70±1.34	135.86±17.64	82.36±10.71
中分位组	84	7.34±2.25^*	7.49±2.14^*	140.57±18.57	85.15±11.70
高分位组	84	7.94±1.91^*	8.22±2.37^*	153.63±23.36^*#	91.64±12.66^*#
F值		25.793	35.510	17.777	13.882
P值		<0.01	<0.01	<0.01	<0.01

Correlation between serum hypersensitive C-reactive protein, lipoprotein-related phospholipase A₂and senile essential hypertension complicated with type 2 diabetes

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 17

Related Articles 15

Recommended Articles

Metrics

Comments

项目	HbA₁c		SBP		DBP
项目	r值	P值	r值	P值	r值	P值
hs-CRP	0.360	<0.01	0.465	<0.01	0.406	<0.01
Lp-PLA₂	0.381	<0.01	0.304	<0.01	0.341	<0.01
HbA₁c	-	-	0.218	<0.01	0.203	0.01

自变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
自变量	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
LDL-C	1.608	0.609	6.970	0.008	4.992	1.513	16.468
HDL-C	-4.659	1.413	10.877	0.01	0.009	0.001	0.151
hs-CRP	3.796	0.825	21.199	<0.01	44.544	8.850	224.208
Lp-PLA₂	0.095	0.021	19.377	<0.01	1.099	1.054	1.147

[1]	Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(1): 34-37.
[2]	Wei Zeng, Cao Ling, She Dunmin, Liu Yan, Wang Yan, Zhang Zhenwen. The causes of death in 54 patients with type 2 diabetes mellitus complicated with COVID-19 [J]. Clinical Focus, 2023, 38(9): 806-812.
[3]	Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 581-587.
[4]	Li Zhiyong, Li Xing. Clinical value of multimodal ultrasound in screening middle cerebral artery stenosis in hypertensive patients [J]. Clinical Focus, 2023, 38(7): 613-617.
[5]	Ni Yiyun, Liu Bin, Liang Qi, Li Xiaofeng. Values of IL-6 and CRP in predicting the severity of coronavirus disease 2019: A meta-analysis [J]. Clinical Focus, 2023, 38(6): 493-499.
[6]	Cheng Tingting, Qi Caiying, Zhang Xuelian, Xiao Meng, Sui Weihang, Li Xiaoyan, Liu Jianying. Analysis of correlations between serum severe mycoplasma pneumoniae pneumonia level with immunoglobulin E and C-reactive protein in children [J]. Clinical Focus, 2023, 38(5): 433-437.
[7]	Yang Minxing, Sun Lu, Ye Yun, Xu Wendong, Huang Xiaolin, Zhang Haiyun, Xu Yinglei. Characteristics of cognitive function and corresponding factors in young and middle-aged patients with type 2 diabetes with obstructive sleep apnea hypopnea syndrome [J]. Clinical Focus, 2023, 38(3): 216-220.
[8]	Li Nana, Jiang Shan. Predictive values of serum homocysteine, cystatin C and high sensitive C-reactive protein levels on heart failure after percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction [J]. Clinical Focus, 2023, 38(2): 121-125.
[9]	Li Huifang, Miao Xia. Prediction of thyroid hormone level on risk of type 2 diabetes nephropathy [J]. Clinical Focus, 2023, 38(2): 137-142.
[10]	Zhu Chenglou, Wu Qiong, Da Mingxu. Risk assessment of pancreatic cancer in patients with type 2 diabetes mellitus treated with sitagliptin: A meta-analysis of randomized controlled trials [J]. Clinical Focus, 2023, 38(12): 1061-1066.
[11]	Liu Yi, Cui Kun, Liu Chang, Zhao Haotian, Li Li, Xue Hongyuan. Correlation between serum secreted frizzled-related protein 5 and early renal damage in patients with essential hypertension [J]. Clinical Focus, 2023, 38(12): 1073-1077.
[12]	Liao Kunfeng, Yao Yisong, Yang Jinpan, Yang Xining, Li Yaru, Zhou Hongyan, Liang Piao. Status and influencing factors of fear of progression in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(12): 1095-1100.
[13]	Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2023, 38(11): 996-1001.
[14]	Xu Yang, Xue Ling. Influencing factors for mild cognitive impairment in type H hypertension patients combined with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(10): 887-892.
[15]	Ding Siqi, Liu Shihua, Zhang Chao, Zhong Ping, Cao Li. Risk factors for epilepsy after delayed post-stroke epilepsy and its clinical correlation with blood Hcy, hs-CRP and D-D [J]. Clinical Focus, 2023, 38(10): 893-897.